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Abstract. Glioblastoma multiforme is the most aggressive type of glioma, with limited 
treatment and poor prognosis. Despite some advances over the last decade, validation of 
novel and selective antiglioma agents remains a challenge in clinical pharmacology. 
Prior studies have shown that leguminous lectins may exert various biological effects, 
including antitumor properties. Accordingly, this study aimed to evaluate the 
mechanisms underlying the antiglioma activity of ConBr, a lectin extracted from the 
Canavalia brasiliensis seeds. ConBr at lower concentrations inhibited C6 glioma cell 
migration while higher levels promoted cell death dependent upon carbohydrate 
recognition domain (CRD) structure. ConBr increased p38MAPK and JNK and decreased 
ERK1/2 and Akt phosphorylation. Moreover, ConBr inhibited mTORC1 
phosphorylation associated with accumulation of autophagic markers, such as acidic 
vacuoles and LC3 cleavage. Inhibition of early step of autophagy with 3-MA partially 
protected whereas the later autophagy inhibitor Chloroquine had no protective effect 
upon ConBr cytotoxicity. ConBr also augmented caspase-3 activation without affecting 
mitochondrial function. Noteworthy, the caspase-8 inhibitor IETF-fmk attenuated 
ConBr induced autophagy and C6 glioma cell death. Finally, ConBr did not show 
cytotoxicity against primary astrocytes, suggesting a selective antiglioma activity. In 
summary, our results indicate that ConBr requires functional CRD lectin domain to 
exert antiglioma activity, and its cytotoxicity is associated with MAPKs and Akt 
pathways modulation and autophagy- and caspase-8- dpen ent cell death. 










1. Introduction  
Glioblastoma multiforme (GBM) is considered the most aggressive primary 
malignant brain tumor of the central nervous system (CNS) in adults, with a median 
survival of 14.2 months despite some advances in therapy over the last decades [1,2]. 
Numerous genetic alterations, such as gene mutations, deletions and amplifications, as 
well as intratumoral heterogeneity, are associated with the fast-proliferation and highly 
invasive phenotypes that lead to rapid tumor progression and poor prognosis in high-
grade gliomas [1]. The cellular phenotypes observed in GBM demonstrate a connection 
between mutated gene and modification of key cell survival pathways, including 
PI3K/PTEN-Akt-mTORC1 and MAPK pathways, to cite a few [2,3]. It has been 
suggested that overexpression of N-acetylgalactosaminyltrasferase 2 (GALNT2), an 
enzyme that regulates the initial step of mucin O–glycosylation, facilitates the 
malignant characteristic of glioma by influencing the O-glycosylation and 
phosphorylation of EGFR and the subsequent downstream PI3K/Akt/mTOR pathway in 
vitro and in vivo   [4]. Moreover, it has been demonstrated that drug-resistant cancer 
cells typically express distinctive glycosylated antigens [5]. Overall, it is well 
established that glycan alteration may lead impairment of cell-cell adhesion, activation 
of oncogenic signaling pathways, deregulation in proliferation and cell death 
mechanisms, induction of pro-metastatic phenotypes and trigger adaptive 
chemoresistance [6,7]. Regarding the importance of glycosylation in pathophysiology of 
cancer, the use of molecules capable of recognizing these differentiated structures has 
only drawn more attention in the last years, with the availability of a crescent number of 
studies characterizing the structure of animal and plant lectins. These facts call for the 
development of novel antiglioma compounds capable of inhibiting survival responses 
using glycosylated molecules as molecular targets [2,5].  
Lectins are a ubiquitously distributed group of proteins of nonimmune origin 
that containing at least one non catalytic domain (carbohydrate recognition domain; 
CRD) that selectively recognizes and reversibly binds to specific free sugars, as well as 
carbohydrate structures present on glycoproteins and glycolipids [8–10]. Lectins 
extracted from plants comprise a group of homologous proteins that assumed to play an 
important role in plant resistance and development, and which have captured 
pharmacological and biological interest. For example, with their ability to recognize 










lectins have been suggested as a potential tool for recognition of cancer cells and 
selective treatment [11–16]. 
Legume seeds are a rich source of lectins, and several g nres of the Diocleinae 
subtribe showed an important source for isolation and characterization of these proteins 
[17–20]. ConA, a lectin isolated one hundred years ago from Canavalia ensiformis 
seeds, displays mannose/glucose-binding specificity [21,22], and it is the foremost 
studied lectin of this subtribe, exhibiting diverse biological actions, including antitumor 
activity via induction of apoptosis [22,23] or autophagy [15,24–26]. After isolation and 
characterization of ConA, other lectins from the same subtribe were purified and 
characterized for their biological effects. Of note, we previously demonstrated that 
ConV (Canavalia virosa lectin), CaBo (Canavalia bonariensis lectin), DLL (Dioclea 
lasiocarpa lectin) and DlyL (Dioclea lasiophylla lectin ) all present cytotoxic effects on 
C6 glioma cells [12,27–29], although the cell death mechanisms remains poorly 
understood. Moreover, the glucose/mannose-specific lectin isolated from the seeds of 
the legume plant Dioclea violacea (DVL) showed more prominent antiglioma activity 
than ConA against C6 [27] and U87 glioma cell lines [30].  
ConBr, a lectin purified 40 years ago from Canavalia brasiliensis seeds, is also 
known as Cow Bean, a native legume (subtribe Diocleinae) of Brazil and South 
America. It is a glucose/mannose-specific lectin largely homologous to ConA, differing 
by only three residues [31,32]. Numerous studies have shown various biological actions 
of ConBr on different targets, including immune and ervous system cells [33–35]. 
Besides, ConBr exerted antiproliferative effects on leukemia [36] and melanoma cell 
lines [37], even though the mechanisms involved in ConBr anticancer effects remain 
unknown. Prior studies from our group have also demonstrated antidepressant-like 
effects of ConBr on animal models, which seems to inv lve induction of Brain-derived 
neurotrophic factor (BDNF) expression in vivo, as well as neuroprotective responses of 
ConBr in vivo and in vitro [38–43]. Therefore, considering the antitumor potential of 
legume lectins and the biological effects of ConBr in different models, the present study 
was carried out to investigate the antiglioma activity of ConBr and the molecular 
mechanism underlying this process. 
 
 
2. Materials and Methods 










High-glucose Dulbecco’s Modified Eagle’s Medium (DME ), trypsin, and fetal 
bovine serum (FBS) were purchased from Gibco®. Penicilli , streptomycin, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Hoechst, Propidium 
iodide (PI), Acridine Orange (AO), Cloroquine (CQ), 3-methyl-adenine (3-MA) and 
Temozolomide (TMZ)  were from Sigma®; FLICE Inibitor (1mM IETD-fmk) was 
obtained from Clontech and Annexin-V-FITC from Life Technology®. The following 
antibodies were acquired as follows: Atg7 (#8558 - Cell Signaling®), LC3A/B (#12741 
- Cell Signaling®), Beclin-1 (#3495- Cell Signaling®), pmTORC1(#2971 – Cell 
Signaling®), mTORC1 (#2972 – Cell Signaling®), pJNK (#92515 - Cell Signaling®), 
JNK (#559304 - Sigma®); pAkt (#92715 - Cell Signalig®), Akt (#46855 - Cell 
Signaling®), pERK1/2 (#M8159 - Sigma®), ERK1/2 (#M5670 - Sigma®), p-p38MAPK 
(#9211- Millipore®), and p38MAPK (#9211- Sigma®), Bak (#12105 – Cell Siganaling®), 
BNIP3 (#3769 – Cell Signaling®), Puma (#12450– Cell Signaling®), Bad (#9239 – 
Cell Signaling®), pBad ((Ser112) #5284– Cell Signali g®) and β-actina (#47778 – 
Santa Cruz®). Rat C6 glioma cells (ATCC-CCL-107) and human U87 glioma cells 
(ATCC/HTB-14) were provided by the Cell Bank of Rio de Janeiro (RJ, Brazil). 
Isolation and culturing of primary cortical astrocytes and Glioblastoma Multiforme 
(GBM1) cultures were performed at Universidade Federal de Santa Catarina (UFSC) as 
described below. All procedures were approved by appropriated local Ethical 
Committees. 
 
2.2 ConBr purification 
ConBr was purified from powdered Canavalia brasiliensis seeds as described 
previously [44]. In short, seeds were collected in Ceará State, and ground in a coffee 
grinder (Cadence™ MDR301 Monovolt, Cadence Design Systems, San Jose, CA, USA) 
to obtain a fine powder. Soluble proteins were extracted in 150 mmol L-1 NaCl (1:10 
w/v) under continuous stirring by 4 h at 25 °C, followed by centrifugation at 10,000 x g 
at 4 °C for 20 min. The supernatant was applied to a Sephadex G-50 column (5 x 25 
cm) previously equilibrated with 150 mmol L-1 NaCl containing 5 mmol L-1 CaCl2 and 5 
mmol L-1 MnCl2. Unbound proteins were eluted with the same equilibration solution. 
The bound lectin was eluted with 0.1 M glycine (pH 2.6) containing 150 mmol L-1 
NaCl, subsequently dialyzed against distilled water, and then lyophilized. The purity of 











2.3 Glioma cell cultures 
The rat C6 glioma cell line and human U87 glioma cell line were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplement d with 10% (v/v) fetal 
bovine serum (FBS) (Gibco®), 100 units/mL penicillin and 100 mg/mL streptomycin 
(Gibco®), at 37 °C in a humidified atmosphere of 95% air and 5% CO2 [27, 30]. GBM-
1 cells were isolated from a GBM tumor surgically taken from a 64 years-old female 
patient at Hospital Celso Ramos Hospital in Florianopolis, Santa Catarina [45]. The 
tumor was collected in 15 mL DMEM: Nutrient Mixture F-12 (DMEM-F12) containing 
10% FBS, cerebral meninges and blood vessels were removed, and the tissue was 
mechanically dissociated with trypsin and the aid of a Pasteur pipette. Then the cells 
were washed with phosphate buffer saline (PBS) (140 mM NaCl, 3 mM KCl, 10 mM 
Na2HPO4 and 2 mM KH2PO4, pH 7.4) and cultured in petri dish containing DME-F12 
plus glucose (0.6%), glutamine (2 mM), sodium bicarbonate (0.06%) and 
penicillin/streptomycin (100 units/ 100 µg for mL) and supplemented with 10% FBS. 
The cells were kept at 37 °C in a humidified atmosphere of 95% air and 5% CO2. All 
procedures and patient consent forms were approved by the UFSC Human Research 
Ethics Committee (CEPSH protocol number 108.286).  
 
2.4 Treatments  
 
For an initial screening, after reaching cell confluence, C6, U87MG and GBM1 
cells were treated with ConBr 1, 10, 30 and 50 µg/mL (10, 100, 300 and 500 nM, 
respectively) or vehicle for 24 h (Supplementary Figure X1) and cell morphology and 
viability (MTT assay) were assessed. C6 glioma cells were chosen to continue the 
experiments. Hence, they were seeded in 96-, 48- or 6-well plates, respectively, and 
incubated for 24 h at 37 °C in an incubator at 80% confluence, the culture medium was 
changed, and the cells were incubated in complete DMEM containing either vehicle or 
ConBr lectin 1, 10, 30 or 50 μg/mL concentrations for different time points depending 
on the experiment. C6 glioma cells treated with multiple concentrations of TMZ (100, 
200, 300, 400 and 500 µM) for 24 h were used as a positive control in order to compare 
the magnitude effect of ConBr with a clinically approved antiglioma agent 
(Supplementary Figure X4). ConBr was dissolved with HEPES–saline buffer without 
glucose composed of NaCl 124 mM, KCl 4 mM, MgSO4 1.2 mM, HEPES 25 mM, and 










vehicle (HEPES–saline buffer without glucose). To evaluate whether the action of 
ConBr was dependent on its carbohydrate-recognition domain, ConBr was blocked by 
diluting the lectin in glucose-free HEPES-saline buffer containing 0.1 M of its specific 
binding sugar (α-methyl-D-mannoside) and maintained for 30 minutes at 37 °C before 
treating cells. Aiming to evaluated the role of autophagy and caspase-8 in C6 glioma 
cell viability, we performed experiments with 3-methyl-adenine (3-MA), Chloroquine 
(CQ, Sigma®) and FLICE inhibitor (1mM IETD-fmk) from Clontech® [46,47]. 3-MA 
inhibits autophagy by blocking autophagosome formation via the inhibition of class III 
PI3K [48] and CQ is a fusion blocker between autophagosome and lysosome [49,50]. 3-
MA and CQ were used at 2 mM and 10 µM concentrations, respectively, added to the 
cells at 1 h prior to ConBr treatment. IETD-fmk was used at 2 µM pretreatment for 6 h 
prior to ConBr incubation.  
 
2.5 Light microscopy 
 Morphological alterations of glioma cells in response to lectin treatment were 
evaluated in cells seeded in 96-well plates at 104 cells/well, and incubated for 3, 6, 12, 
24 or 48 h with ConBr. At the end of treatments, the cells were observed by light 
microscopy by using an inverted NIKON eclipse T2000-U microscope. 
 
2.6 MTT assay 
Cell viability was estimated by MTT (Sigma®) [30-(4,5-dimethylthiazol-2yl) 
2,5-diphenyltetrazolium bromide] reduction assay as previously described [51]. Briefly, 
glioma cells were seeded in 96-well plates at 104 cells/well and incubated for 24 h with 
vehicle or ConBr. In addition, the C6 cells were tra ed by 3, 6, 12, 24 or 48 h with the 
same treatment to perform a time/concentration response curve. After treatment, the 
medium was removed, and cells were incubated for 1 h at 37 oC with 100 µL of 0.5 
mg/mL MTT dissolved in HBSS.  Reduced MTT formazan crystals were dissolved with 
100 µL dimethylsulfoxide (DMSO) for 30 min at 37 oC, and the absorbance evaluated at 
540 nm using a Tecan® Microplate Reader Infinite M200 reader, equipment at the 
Laboratório Multiusuário de Estudos em Biologia at the Universidade Federal de Santa 
Catarina (LAMEB/UFSC). The results were expressed as a percentage of the 
control/vehicle group (considered as 100% viable).  
 










The leakage of LDH into the cell culture medium was measured as an estimate 
of cell membrane integrity, as described by Rosa et l. [52]. To this end, C6 glioma 
cells were seeded in a 96-well plate at 104 cells/well and incubated for 12 or 24 h with 
vehicle or ConBr. At the end of treatments, 50 μL of cell culture medium was mixed 
with 200 μL of 0.5 M potassium phosphate buffer containing pyruvate, NaHCO3 and 
NADH, and the kinetics of LDH enzymatic activity was monitored at 340 nm using an 
Infinite M200 (Tecan®) reader. Cells incubated with 0.02% Triton-X100 (added 15 min 
prior to medium harvesting) were used as a positive control for LDH activity. Delta 
NADH absorbance was converted to percentages relativ  to positive controls (Triton-
X100 treated cells; considered as 100% LDH leakage). 
 
2.8 JC-1 assay 
The mitochondrial membrane potential (ΔΨm) was measured using the 5,5ʹ,6,6́-
tetrachloro-1,1́,3,3́-tetraethyl-benzimidazolyl carbocyanine iodide (JC-1) 
(modifications of De Biasi et al. [53]). C6 cells were seeded in 96-well plates at 104 
cells/well for 24 h and then treated for 6 h with vehicle/control or ConBr. Carbonyl 
cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP, 1 µM; Sigma®) treated cells 
were also carried out as a positive control for mitochondrial depolarization. At the end 
of treatments, de medium was replaced with 0.1 mL of 1 mM JC-1 solution, and the 
cells incubated for 20 min at 37 °C protected from light. Thereafter, the cells were 
washed with PBS (140 mM NaCl, 3 mM KCl, 10 mM Na2HPO4 and 2 mM KH2PO4, 
pH 7.4), followed by the addition of 0.1 mL/well PBS. Fluorescence was measured in a 
Spectramax Paradigm Microplate Reader (Molecular Devices®, Sunnyvale, CA, USA) 
set at 490 nm excitation and 520 nm emission for detection of red fluorescence (J-
aggregates) and 525 nm excitation and 590 nm emission for green detection (JC-1 
monomers). The values of red/green fluorescence ratio of each sample were converted 
to percentages relative control/vehicle-treated cells. The assays were performed in 4 
independent experiments in triplicate. 
 
2.9 ROS assay 
 Reactive oxygen species (ROS) production was evaluated by using the 2,7-
dichlorodihydrofluorescein diacetate (H2DCF-DA) fluorescent probe [29]. Briefly, C6 
cells were plated in a 96-well plate at 104 cells/well for 24 h and then treated with 










PBS, and then 100 μL of 10 μM H2DCF-DA was incubated at 37 °C for 20 minutes. 
The H2DCF-DA solution was discarded, the cells were washed with PBS, and 100 μL 
PBS was added for fluorescence reading at 485/520 nm (excitation/emission) using a 
SpectraMax® reader (Molecular Devices), equipment at the Laboratório Multiusuário 
de Estudos em Biologia at the Universidade Federal de Santa Catarina 
(LAMEB/UFSC). Cells treated with 100 µM hydrogen peroxide (H2O2) for 15 minutes 
were used as a positive control for ROS production.  
 
2.10 Acridine Orange staining of acidic vesicular organelle 
 Acridine Orange (AO) assay was performed to evaluate cidic vesicular 
organelle (AVO) formation by ConBr. C6 cells were seeded in a 96-well plate at 104 
cells/well for 24 h in complete DMEM. Then, C6 cells were treated with vehicle 
(control) or ConBr for 3, 6, 12, 24 or 48 h,  after reatment period, 50 µL of culture 
medium was removed and was added 20 µL of AO (10 μg/mL; Sigma®) for 20 min in 
the dark at 37 ºC (modifications of Singh et al. [54]). The cells were visualized by an 
inverted NIKON eclipse T2000-U microscope using filter sets of 470 nm excitation and 
525 nm emission for chromatin (CR; green fluorescence) and 350 nm excitation and 
615 nm emission for acidic vesicular organelles (AVO; orange/red fluorescence) 
detection. 
 
2.11 Propidium Iodide staining 
For Propidium Iodide (PI) assay, C6 cells were seeded in a 96-well plate and 
treated in the same conditions as described for the Acridine Orange assay. At the end of 
treatments, the cells were incubated with Hoechst (1 mg/mL - Sigma®) and PI (1 
mg/mL - Sigma®) at final concentration of 0.015 mg/L for 15 min in the dark 
(modifications of Singh et al. [54]). The cells were visualized in an inverted NIKON 
eclipse T2000-U microscope using filter sets of 488nm excitation and 560 nm emission 
for PI and 353 nm excitation and 483 nm emission for H echst. 
 
2.12 Transmission electron microscopy (TEM)  
TEM analysis was performed as previously described by De Paul et al. [55]. C6 
cells (6 x106 cells) were seeded in 25 cm2 flasks and cultured for 24 h. Afterwards the 
medium was replaced with a new medium containing vehicl  or ConBr at 30 μg/mL for 










Karnovsky mixture containing 4% formaldehyde and 2%glutaraldehyde in 0.1 M 
cacodylate buffer plus 7% sucrose. Then, the cells were treated with 1% OsO4 for 1 h, 
followed by staining-in-block with 1% uranyl acetate in 0.1 M acetate buffer pH 5.2 for 
20 min. After dehydration with a series of graded cold acetone, the cells were embedded 
in Araldite resin (Electron Microscopy Sciences, Hatfield, PA). Thin sections were cut 
using a JEOL ultramicrotome (Nikon, Tokyo, Japan) with a diamond knife and then 
stained with uranyl acetate/lead citrate and examined using a Zeiss Leo 906-E electron 
microscope equipped with the digital camera Megaview III (Oberkochen, Germany), 
equipment at the Centro de Microscopía Electrónica at the Universidad Nacional de 
Córdoba, Facultad de Ciencias Médicas.  
 
2.13 Annexin-V-FITC/PI apoptosis assay 
For apoptosis assay [27], C6 cells (5x105 cells/well) were seeded in a 6-well 
plate for 24 h and treated with ConBr (10, 30 and 50 µg/mL) or vehicle for 6 h. At the 
end of treatments, the cells were trypsinized and pooled to obtain 106 cells per sample. 
The samples were centrifuged at 1,154 x g for 5 min and the pellet suspended in 200 μL 
of binding buffer (10 mM HEPES, 140 mM NaCl and 25 mM CaCl2, pH 7.4) followed 
by incubation with 2 μL of Annexin-V-FICT (Life technology®) and 2 μL of Propidium 
Iodide (1mg/mL) (Sigma®) for 15 min in the dark.  Staurosporin (1 μM; 3 h) treated 
cells were used as a positive control for Annexin-V-FITC externalization. Ten thousand 
events per sample were collected using a FACS Comer Device (Becton Dickson®) 
equipment at the Laboratório Multiusuário de Estudos em Biologia at the Universidade 
Federal de Santa Catarina (LAMEB/UFSC). The data were analyzed in Flowing 2.5.1® 
software, using FITC (515-545 nm) and PE (564-606 nm) channels for analysis of 
Annexin-V-FITC and Propidium Iodide, respectively.  
 
2.14 Caspase-3 activation Assay 
 In order to investigate the capability of ConBr in to activate casp-3 was used of 
EnzChek® caspase-3 Assay Kit [27].  C6 cells were plated at a density of 5x105 
cells/well in 6-well plate, and treatment for 6 h with vehicle or ConBr. A positive 
control was performed with Staurosporine (1 µM). Two ells were subjected to the 
same treatment concentration and joined to obtain a f al reaction of 106 cells. After 
treatment, culture medium was removed and cells trypsinized and centrifuged at 3,846 x 










lysis process. Subsequently, the trader’s protocol was performed. To obtain data, 
samples were subjected to a 1 h closed kinetic test, each reading being taken every 30 
seconds, under the following conditions: 342 nm excitation, 435 nm cut-off and 446 nm 
emission.  
 
2.15 Western Blot 
 C6 cells were seeded in a 6-well plate at the density of 25x104 cells per well for 
24 h. Then, the cells were treated with vehicle (control) or ConBr in serum-free DMEM 
for 12 h. At the end of treatments, cells were homogenized in 200 μL Stop Solution 
(Tris 50 mM, EDTA 2 mM, SDS 4%, pH 6.8) as previously described by Nascimento et 
al. [27]. Proteins extracts (30 μg/sample) were electrophoresed in 6, 10, 12% SDS-
PAGE minigels and transferred onto nitrocellulose mmbranes using a semi-dry 
blotting apparatus (1.2 mA/cm2 by 1.5 h). Transfer efficiency was confirmed by 
Ponceau S staining of membranes. The immunodetection of Atg7, LC3A/B, Beclin-1, 
pJNK (Thr183/Tyr185), JNK; pAkt (Ser473), Akt, pmTORC1(Ser2448), mTORC1, 
Bak, Puma, Bad, pBad (Ser112) and BNIP3 at 1:1,000 dilution; pERK1/2 
(Thr202/Tyr204) at 1:5,000 dilution; ERK1/2 at 1:20,0 0 dilution; p-p38MAPK 
(Thr180/Tyr182) and p38MAPK at 1:10,000 dilution was performed by overnight 
incubation with the respective primary antibody diluted in Tris-buffered saline Tween 
20 (TBS-T) containing 2% BSA. β-actin detection (1:2,500 dilution) was used as the 
loading control. Unless otherwise specified, secondary antibodies were incubated at 
1:1,000 dilution. Thereafter, the membranes were washed in TBS-T and incubated for 1 
h at room temperature with horseradish peroxidase (HRP)-conjugated anti-IgG-
rabbit/mouse antibodies as appropriate. The bands were developed by 
chemiluminescence substrate (Super ECL, GE®) on the C imidoc MP, equipment at 
the Laboratório Multiusuário de Estudos em Biologia at the Universidade Federal de 
Santa Catarina (LAMEB/UFSC). The bands and OD were captured and quantified using 
the Image Lab® software (Bio-Rad). The phosphorylation levels of ERK1/2, p38MAPK, 
JNK, Akt and mTORC1 were quantified by densitometry and OD (optical density) ratio 
of phospho/total levels were calculated. The measurement of LC3 was performed by 
dividing the OD of each form of LC3 (I and II) by the OD of β-actin. Hence, in order to 
express the ratio of LC3 cleavage, normalized OD of LC3II was divided by normalized 
OD of LC3I. Atg7, Beclin-1, Bak, Puma, p-Bad, Bad and BNIP3 were measured by 











2.16 Cell migration (Scratch assay) 
C6 glioma cells were grown to confluence in 48-well plates (5x104 cells/well), 
and then a wound was introduced in each well by scraping cell layers with a P200 
pipette tip. The cells were washed with PBS to remove any loosely held cells [56]. 
Thereafter, serum-free DMEM containing vehicle (contr l) or ConBr. Images were 
captured at 0, 24 and 48 h treatment time points by an inverted NIKON eclipse T2000-
U microscope. Percentage of wound closure was calculated using Image J software. 
 
2.17 Cell migration (Transwell assay)  
Given that cell proliferation could interfere with scratch assays, we performed 
Transwell assays as a complementary method to assess anti-migration effects of ConBr 
in gliomas [27]. Briefly, the transwells were placed in a 24-well plate, and then C6 cells 
(5 x 104 cells suspended in 100 μL DMEM) were plated onto the top chamber. Top 
chamber plated cells were then treated with vehicle/control or ConBr at 30 and 50 
μg/mL. Ten minutes after addition of each treatment, the bottom chamber was filled 
with 600 μL/well of DMEM-F12 medium supplemented with 20% FBS as a 
chemoattractant and incubated for additional 24 h. After, the transwells were removed, 
and the remaining/nonmigrated cells within the top chamber were removed with the aid 
of a swab. Subsequently, each transwell was stained with Crystal Violet, and the 
migrated cells were visualized under light microscopy and counted. The migration ratio 
for each treatment was compared to control/vehicle treatments (considered as 100%). 
 
2.18 Molecular Docking Analysis of interaction of ConBr to MMP-1 glycans 
Molecular docking was performed using GOLD software v. 5.5 (CDCC, 
Cambridge, England). Structural coordinates of ConBr was obtained from PDB under 
id: 4H55). MMP-1 glycans were prepared using Carbohydrate Builder server 
(http://glycam.org), applying the glycans structures from the work of Saarinen et al. 
[57]. The center of the CRD cavity and all residues in a 10 Å radius were chosen for 
application of the algorithm. PLANTSPLP score function [58] and the following 
parameters were used: population size of 100, selection pressure of 1.1, number of 
operations of 10,000, number of islands of 5, niche siz  of 2, crossover frequency of 95, 
number of poses of 20. Lowest energy poses were chosen by combining the docking 










2.19 Cortical astrocytes culture  
Cortical cultures of astrocytes were prepared from male newborn Wistar rats at 
postnatal day-0 or day-1 (P0/P1) as previously described by Nascimento et al. [30,62]. 
The animals were provided by the Animal Core Facility at the Federal University of 
Santa Catarina (UFSC). All animal procedures were approved by the Institutional 
Animal Care and Use Committee (CEUA/UFSC); Protocol N . 2380161216. Briefly, 
astrocytes were seeded in 24-well plates (3.5 × 104 cells/well) and grown to confluence 
(7–10 days) in DMEM-F12 (Invitrogen, Carlsbad, CA) supplemented with 10 % FBS 
(Cultilab, Brazil) at 37 °C in a humidified 5% CO2 and 95% O2 atmosphere. After 
reaching cell confluence, astrocytes were treated with ConBr (10, 30 and 50 µg/mL) or 
vehicle for 24 h and subsequently assayed for determination of cell viability (MTT 
assay), morphological changes (by optical microscopy), as well as staining with AO and 
PI for determination of autophagy and cell membrane damage, respectively, using the 
same protocols afore described. 
 
2.20 Statistical analysis 
The results were analyzed using GraphPad Prism version, 5.0 (La Jolla, 
California, USA). The data presented normal distribution according to the Shapiro-Wilk 
test (p<0.05) and therefore were evaluated by Analysis of Variance (One-way, Two-
way ANOVA) followed by Bonferroni post-hoc test. P values less than 0.05 (p<0.05) 




3.1 ConBr induces morphological changes and decreased viability in C6 cells 
 In order to evaluate the cytotoxic effect of ConBr in glioma cells, three 
different cell lines were used including: C6 glioma cells, a commercial mouse line; 
U87MG, a commercial human glioma cell line; GBM1, a primary cell line from human 
GBM. The cells were treated for 24 h with vehicle (control) or 1, 10, 30 and 50 μg/mL 
of lectin, and cell morphology and cell viability were assessed by light microscopy and 
MTT assay, respectively. ConBr induced morphological ch nges in all cell lines tested, 
which included modification from a flat to spherical round- shaped morphology. 










Figure X1). Taking the aforementioned results into account, we chose the C6 glioma 
cells line to investigate molecular mechanisms dictating ConBr cytotoxicity.  
 To establish a time and concentration curve response to ConBr, C6 glioma 
cells were incubated for 3, 6, 12, 24 and 48 h with ve icle or lectin (1, 10, 30 and 50 
μg/mL). The results showed that 30 and 50 μg/mL ConBr decreased cell viability after 
12 h treatment, reaching more pronounced effects after 24 and 48 h of exposure as 
determined by MTT assay (Fig. 1A). ConBr toxicity was associated with LDH leakage 
that was detectable from 12 h of treatment with 30 and 50 μg/mL (Fig. 1B). Light 
microscopy analysis showed that ConBr induced changes in cell morphology, including 
changes from a flat to spherical round- shaped morphology, which occurred as soon as 6 
h and remained for at least 48 h incubation (Fig. 1C).  
 We then examined whether ConBr effect on cell viability could be associated 
with cell death induction. For analysis of losses in cell membrane integrity, C6 cells 
were treated with vehicle/control or ConBr and stained with PI. Figure 1E showed that a 
pronounced PI staining occurred from 24 to 48 h exposure to 50 μg/mL ConBr, while 
lower concentrations did not show such aggressive cytotoxicity. Because ConBr 
cytotoxicity is only extensive in the highest concetration and after prolonged exposure 
to the lectin, Figure 1 date collectively indicate that both cytostatic and cytotoxic effects 
may account to ConBr antiglioma activity, and cytotoxicity is possibly mediated by 
controlled (non-necrotic) mechanisms of cell death.  
 
3.2 ConBr antiglioma effect is dependent on tertiary/quaternary structure and 
carbohydrate recognition domain (CRD) 
Aiming to determine whether the cytotoxic effect of ConBr was dependent upon 
its tridimensional structure and CRD, the lectin was submitted to either thermal 
denaturation or blocking of CRD with α-methyl-D-mannopyranoside. Light microscopy 
showed that changes in C6 cell morphology induced by native protein at 30-50 μg/mL 
(24 h) were partially lost by CRD blockage and completely blocked by thermal 
denaturation (Fig. 2A). CRD blockage also abrogated the impairment of cell viability 
induced by native ConBr at 30 μg/mL (Fig. 2B). Cell viability impairment induced by 
ConBr at 50 μg/mL occurred despite the CRD blockage. Denatured ConBr lectin 
exerted no cytotoxicity in C6 cells (data not shown). These results indicate that 










Moreover, the mechanism underlying cytotoxicity of mild concentrations of ConBr (30 
μg/mL) seems to rely on the CRD. 
 
3.3 ConBr decrease capacity of cell migration in C6 cells 
Cellular migration/motility pathways are key drivers of infiltrative behavior of 
glioma in vivo. Scratching assays showed that ConBr induced a significant decrease in 
cell migration, even at low concentrations (Fig. 3A). At 24 h, ConBr treatment 
decreased cell culture wound closure by ~50, 70 and 90% at 1, 10 and 30-50 μg/mL 
concentrations, respectively. Control cells reached a complete closure of the wound 
within 24 h (Fig. 3A). At 48 h, 50 μg/mL of lectin retained its cytostatic effect, whereas 
1, 10 and 30 μg/mL ConBr showed a lower, albeit significant, magnitude of inhibition 
against cell migration if compared to results obtained at the 24 h time point. It should be 
noted that 1 and 10 μg/mL of lectin, in contrast to 30 and 50 μg/mL, showed no 
cytotoxic effects, but these concentrations could inhibit cell migration, indicating that 
ConBr impairs glioma cells, even at noncytotoxic levels. Scratch assay results were 
confirmed by transwell experiments which showed that C6 cells treated for 24 h with 
ConBr at 30 and 50 μg/mL showed 50 and 60 % inhibition of cell migration compared 
with control (Fig. 3B). To assess whether the cytostatic effect of ConBr would be 
related to an interaction in MMP-1 glycans, molecular docking was performed (Fig. 
3D). The tested glycans from MMP1 (Supplementary Figures X2 and X3) were drawn 
following the data found in the work of Saarinen et al. 1999 [57]. The paper indicates 
the presence of glycans specific to normal cells and others found only in tumor cells, 
there are also glycans found in both normal and malign nt cells, although with changes 
in the frequency of appearance. As shown in Table 1, ConBr was able to interact with 
only 1 glycan exclusive to normal cells and 3 glycans present in both cells. On the other 
hand, it managed to interact favorably with most of he glycans present exclusively in 
tumor cells. It was observed that the interactions between the lectins and the glycans 
took place in an internal mannosyl residue (residues from first branch), and no 
interaction with residues in terminal positions have been observed (Fig. 3C-D). 
 
3.4 ConBr modulates MAPKs and Akt pathways in C6 cells 
 Treatment of C6 cells with ConBr for 12 h stimulated the phosphorylation of 
JNKs and p38MAPK, as shown in Figure 4B-C and 4F. JNK(p54) and JNK(p46) 










compared to control (Fig. 4B-C). ConBr at 30 and 50 µg/mL also provoked a 7-fold 
increment in p38MAPK phosphorylation, as compared to control cells (Fig. 4F). On the 
other hand, ConBr decreased the phophorylation of typical glioma survival protein 
kinases, ERK 1/2 (Fig. 4D-E) and Akt, in C6 cells (Fig. 4G). The effect of ConBr on p-
ERK1 was more pronounced since all concentrations tested were effective in decreasing 
ERK1 phosphorylation (Fig. 4D) whereas 50 µg/mL ConBr suppressed Akt 
phophorylation (Fig. 4G). Taken together, this set of results suggests a pattern of ConBr 
effects upon MAPKs and Akt phosphorylation that might result in cell death induction. 
 
3.5 Autophagy and caspase-8 promote cell death in ConBr-treated glioma cells 
 Next, we evaluated the possible cell death pathways triggered by ConBr in C6 
cells. In order to assess apoptosis, C6 cells were stained with Annexin-V-FITC and PI 
and evaluated by flow cytometry. As shown in Figure 5A, only ConBr at 50 μg/mL 
caused an increase of 2.5% in Annexin-V-FITC+/PI- labeling and 13% in Annexin-V-
FITC+/PI+. Differently, PI+ labeling was detectable in 34 and 52% of cells treated with 
30 and 50 µg/mL ConBr, respectively, whereas only 5.23% of cells stained positive in 
control treatments. Noteworthy, this effect was accompanied by caspase-3 activation 
(Fig. 5B), which displayed ~2-fold increase in response to 10 μg/mL and ~3-fold 
increase at 30-50 µg/mL ConBr as evaluated by “EnzChek® caspase-3 Assay Kit”. 
 We also evaluated whether 6 h treatment with ConBr could disrupt 
mitochondrial membrane potential and ROS production, since they are events that could 
be involved in the mechanism of cell death induction by ConBr. However, none 
significant alteration in the mitochondrial membrane potential was observed in response 
to ConBr, as assessed by JC-1 assay (Fig. 5D-E). Moreover, as assessed by H2DCF-DA 
assay, ROS levels decreased in response to ConBr (Fig. 5C). These results suggest that 
ConBr did not affect mitochondrial function as a possible trigger to apoptosis. 
Western blot evaluation of Bak and BNIP3 in total lysates from C6 cells treated 
with ConBr for 12 h was performed. The results did not demonstrate alteration in Bak 
expression compared to control (Fig. 5F and H). However, BNIP3 displayed ~7-fold 
increase of expression in response to ConBr at 30 and 50 μg/mL, as compared to control 
(Fig. 5F and G). In order to evaluate whether activtion of caspase-3 and Annexin-V-
FITC labeling could be related to an extrinsic apoptotic process, as a result of lectin 
binding to glycan residues on death receptor, we tested the effect of caspase-8/FLICE 










demonstrated that IETD-fmk pretreatment blocked the cytotoxic effect of 30 and 50 
µg/mL ConBr in C6 cells after 24 h treatment (Fig. 5I)  
Acridine Orange assays are largely applied to detect acidic vesicular organelles 
(AVO) that occur during autophagy. We observed thatConBr treatment of C6 cells for 
12 h caused a significant increment of AVO labeling from 10 to 50 µg/mL ConBr (Fig. 
6A). Moreover, it is important to highlight that the increase of AVO in response to 
ConBr for 12 h at 10 µg/mL was not accompanied by ac totoxic effect of the lectin in 
C6 cells, as shown at figure 1A. After 24 h exposure, ConBr caused a significant 
increment of AVO at 1 to 50 µg/mL, while after 48 h treatment only 30 and 50 µg/mL 
ConBr enhanced AVO frequency (Fig. 6B). Notably, this result was confirmed by 
transmission electron microscopy (TEM) analysis that showed small vesicles and large 
autophagic (arrows) containing organelles and vesicular structures in the C6 cell 
cytoplasm, in response to 30 µg/mL ConBr treatment for 12 h (Fig. 6C). ConBr-induced 
AVO formation was accompanied by decreased mTORC1 phosphorylation (Fig. 6D-E), 
minor changes in Beclin-1 (Fig. 6D and F) and Atg7 (Fig. 6D and G), and a 3- to 6-fold 
increase in cleavage of LC3I to LC3II (Fig. 6D and H), a key molecular event during 
autophagy, as evaluated by Western blot of total lysates from C6 cells treated for 12 h 
with the lectin. These responses were more significant with 30 and 50 μg/mL ConBr. 
Finally, to identify the role of autophagy in the lectin-induced cell death, C6 cells were 
co-treated with ConBr and 3-MA (2 mM) or CQ (10 µM). Results indicate that 
impairment of cell viability induced by 30 μg/mL ConBr were abrogated by inhibition 
of early steps of autophagy with 3-MA, while the effect of 50 μg/mL ConBr was 
partially blocked by 3-MA (Fig. 6I). Blockage of later autophagy with CQ did not cause 
a significant protection of the cytotoxic effect of ConBr (Fig. 6J). 
To corroborate a mechanism of crosstalk between caspase-8 activation and 
autophagic degradation, we evaluated the response of c lls to pre-treatment with 3-MA 
or FLICE inhibitor and subsequent co-treatment with 30 µg/mL ConBr for 12 or 24 h. It 
was observed by morphological analysis (Fig. 7A) and MTT assay (Fig. 7B) that the 
cytotoxic effect of ConBr (24 h) was abrogated by trea ment with 3-MA or FLICE. 
Concerning the expression of apoptotic and autophagy proteins it was observed that 
ConBr (12 h) increased the expression of BNIP3 (Fig. 7C and 7D), Puma (Fig. 7C and 
7E) and induces LC3I cleavage (Fig. 7C and 7G) with no changes in Bad (Fig. 7C and 
7F). Notable, 3-MA or FLICE pre-treatment was able to block the ConBr effect (Fig. 










this process appears to mediate ConBr toxicity to C6 cells. Furthermore, these results 
suggest that there exists a crosstalk mechanism between caspase-8 activation and 
autophagic process induced by the lectin.  
 
3.6 ConBr did not affect the viability of primary culture from telencephalon 
astrocytes 
 To evaluate the cytotoxic effect of ConBr in normal glial cells, primary cell 
cultures of astrocytes were prepared from rat telenc phalon and subjected to 24 h 
treatment with vehicle or ConBr at 10, 30 and 50 μg/mL. Light microscopy (Fig. 8A) 
showed no changes in astrocyte morphology in response to ConBr. ConBr treatment 
also had no impact on astrocyte viability, as evaluated by MTT assay (Fig. 8B). In 
keeping with the above-mentioned results, PI/Hoechst staining showed no evidence of 
losses in cell membrane integrity in ConBr-treated astrocytes (Fig. 8C). In addition, 
AVO formation was also not altered by ConBr as compared to control (Fig. 8D). Taken 
together, these data indicate a selective effect of ConBr targeting glial tumor cells while 
sparing normal astrocytes. 
 
 
4. Discussion  
Despite the advances in oncogenomics and targeted therapeutics for a variety of 
cancers, GBM treatment remains a major challenge in clinical oncology. Even the most 
promising compounds from preclinical studies, such as EGFR as PTEN/Akt inhibitors, 
failed to provide survival benefits in clinical trials over the last decade [63,64]. Thus, 
novel compounds exhibiting tumor selectivity and efficacy to eliminate cancer cells are 
urgently needed. An essential first step in achieving this goal is the search for new 
therapeutic targets and a better understanding of the cell signaling mechanisms 
underlying the inhibition of cell migration and proliferation, as well as the induction of 
glioma cell death. In recent decades, lectins have been used as a tool for differentiation 
between malignant and benign tumors, especially for the ability to recognize specific 
glycosylation patterns, some of which are associated with the metastatic process 
[9,13,65,66]. In addition, it has been reported that pl nt lectins may directly exert 
antitumor effects in different cancer models [9,13,15,66]. In the last years, our group 
has demonstrated cytotoxic effect of different lectins isolated from the subtribe 










bonariensis (CaBo), Canavalia ensiformis (ConA), Dioclea lasiophylla (DlyL), Dioclea 
lasiocarpa (DLL) and Dioclea violacea (DVL) in C6 and U87MG glioma cell lines 
[12,27–30]. Herein we extended these previous studies by showing ConBr cytotoxicity 
against three glioma cells lineages and, utilizing the C6 glioma cell model, we 
uncovered the cytotoxic mechanism and molecular signaling pathways potentially 
involved in the autophagic cell death triggered by ConBr.  
The effect of ConBr on C6 glioma cells, U87MG and GBM1 included changes 
in cell morphology from a flat to spherical rounded shape, an effect that was 
accompanied by a decrease of cell viability in the C6 and GBM1 cells, but not in the 
U87MG lineage. Hence, C6 glioma cells showed to be largely sensitive to ConBr, since 
the lectin decreased C6 glioma cell viability by 60% at concentrations equal to, or 
higher than, 30 μg/mL after 12 h of treatment. Regarding these set of results, it is 
important to state that our previous studies showed that ConA promoted losses in C6 
glioma cells viability only after 24 h of treatment [27]. Moreover, ConA produced 
cytotoxicity against U87MG cells only after long periods (up to 48-96 h) of treatment 
[30]. Noteworthy, our results concerning the activity of ConBr on U87MG cell line 
viability appears to be in line with this previous study. 
Another aspect to be considered is related to the pot ncy of ConBr when 
compared to an antiglioma drug of clinical use. Temozolomide (TMZ) is the standard 
chemotherapy agent used for GBM treatment [67–69], even though most of the patients 
frequently develop chemoresistance and succumb to the disease [70]. Hence, we 
establish a comparative between the cytotoxic effect of ConBr and TMZ on C6 glioma 
cells treated for 24 h. Notable, ConBr 30 µg/mL (300 nM) displayed an effect like TMZ 
400 µM (Supplementary Figure X4), showing that the activity of ConBr on C6 cells is 
relevant and with magnitude comparable with a standard drug applied for GBM 
chemotherapy.  
ConBr and ConA display high similarity of amino acid sequence and crystal 
structure. However, differences of biological activities have been well documented for 
these lectins [33,34]. Moreover, other lectins of the genre Canavalia, such as CaBo and 
ConV, showed similar effect only after 24 h treatment and at higher concentration (50-
100 μg/mL) [28,29]. These data highlight that ConBr is app rently more cytotoxic to C6 
cells than ConA, ConV or CaBo by its strong decrease in C6 cell viability, despite the 
homology of structural similarity and carbohydrate affinity. Thus, it reinforces the 










fundamental aspect demonstrated in the present study howed that ConBr cytotoxicity 
to glioma cells depends on its three-dimensional structure and CRD (Fig. 2).  
ConBr-induced decrease in cell viability by MTT assy may be the product of 
either cell death or decreased cell proliferation. Double staining with Hoechst/PI and 
LDH release assays (Fig. 1B and D) indicated that ConBr is cytotoxic owing to 
increased PI incorporation and LDH leakage, especially at the higher concentrations 
(30-50 μg/mL). Noteworthy, lower ConBr concentrations were not cytotoxic, even 
though decreased cell migration/proliferation was ob erved (Fig. 3A and B). Matrix 
metalloproteinases (MMPs), that in humans comprise 23 nzymes, are a family of zinc-
dependent endoproteases that acts on extracellular matrix (ECM) and cell surface 
proteins, promoting matrix remodeling, enzyme activity regulation and release of 
mitogenic growth factor and bioactive molecules. Hence, MMPs represent key 
regulatory proteins that can control cell proliferation, migration and differentiation [71–
73]. Diverse MMPs members have been implicated in tumor progression and 
invasiveness. Noteworthy, MMP-1, MMP-2, MMP-9 and the membrane type 1 (MT1)-
MMP (also known as MMP-14) have been reported to be involved in the migratory and 
invasive properties, as well as malignancy grade and clinical outcome of gliomas 
[74,75]. MMP-1, which the expression is regulated by EGF/ERK1/2 signaling, displays 
a core of glycans [57,73] and is well documented for its specific role in glioma 
migration, invasion, and malignance grade [75–78]. Hence, the ConBr inhibition of 
glioma migration may be postulated to occur by the ConBr´s ability to bind glycans 
mainly expressed on     MMP-1 present in tumoral cells (Fig. 3D). Notable, previous 
studies showed that ConA displays the capability to modulate other members of the 
metalloproteinase family, the membrane type 1 metalloproteinase (MT1-MMP/MMP-
14) [79]. Hence, treatment of U87 cells with ConA promoted increment of COX-2 
expression, dephosphorylation of Akt and modulation of IKK-NF-kB signaling [25], as 
well as activation of JAK/STAT pathway and autophagy ene transcription by 
mechanism apparently dependent of MT1-MMP/MMP-14 modulation [80]. In spite of 
all these aspects, there are no reports indicating MMP-1 modulation by lectins. Thus, 
the molecular docking assay performed in our study showed for the first time that a 
legume lectin interacts favorably with glycans of MMP-1 and ConBr obtaining better 
scores than ConA (data not shown). Future studies will be necessary to address the 
participation of MMP-1 in the mechanism of cell death or inhibition of cell migration 










a preferential binding of ConBr with MMP-1 glycans expressed in tumoral cells. 
Particularly, most of the biological activities elicited by lectins are related to their 
capability to bind carbohydrates/glycans which leads to a biological effect [81]. Thus, 
the more pronounced expression of MMP-1 in high grade glioma cells [75,82], together 
with preferential binding of ConBr to glycans express d in tumoral MMP-1, may 
illustrate the potential of selective activity of ConBr against glioma cells rather than 
astrocytes or neurons. 
 ConBr at higher levels caused a remarkable increase in p38MAPK and JNKs 
phosphorylation and promoted inhibition of ERK1/2 and Akt phosphorylation (Fig. 4). 
These pathways are well documented to be associated wi h cell migration, as well as 
cell death and survival [83–86]. Indeed, it has been d monstrated that these kinases are 
also involved in apoptosis and autophagy modulation [8,86,87]. As example, activation 
of JNK was reported to activate Beclin-1 and inhibits Bcl2 [88]. Therefore, future 
studies addressing the participation of JNKs and p38MAPK in the mechanism of cell 
death induced by ConBr will be necessary. Taken together, our data show that ConBr 
triggers a series of antitumor effects and positively modulates protein kinases associated 
with stress and cell death and negatively modulates protein kinases associated with cell 
survival and proliferation. 
As shown in Figure 5A, only ConBr at 50 μg/mL caused a small increase of 
Annexin-V-FITC labeling differently that PI labeling was detectable with 30 and 50 
µg/mL ConBr, accompanied by caspase-3 activation (Fig. 5B). It is well documented 
that PI labeling is associated with cell death due to necrosis. However, this staining may 
also be related to a final process of apoptosis. In addition, fragments of apoptotic cells 
that are not phagocytized (common in cell cultures), due to lack of cells that perform 
this function in culture’s microenvironment, end us suffering a type of degradation that 
resembles necrosis, receiving the denomination of secondary necrosis [89]. Moreover, 
no alteration in mitochondrial membrane potential nor significant changes in the 
expression of pro-apoptotic effector protein Bak was detected. While ROS production 
was in fact decreased by ConBr, different from the eff cts observed in cells treated with 
ConA [25,27,30,36].  
Proteins of the B cell lymphoma 2 (Bcl-2) family in mammals are involved in 
modulation of cell survival and apoptosis, and include all proteins containing at least 
one of the four regions called Bcl-2 homology (BH1-4) domains. The pro-survival 










four BH domains. The pro-apoptotic proteins can be divided in two distinct groups: one 
that encompass Bak and Bax, which is capable to promote mitochondrial 
permeabilization and contain four BH domains; the second is represented by the BH3-
only proteins (Bim, Puma, Bid, Bad, NOXA, Bik, HRK and BMF) that contain only the 
BH3 domain. The pro-apoptotic BH3-only proteins such as Bad and Puma can act as 
sensors of cellular stress. Indeed, they can bind and inactivate specific pro-survival 
proteins, such Bcl-2 and Bcl-XL, or bind directly to Bax and Bak triggering apoptosis. 
Moreover, anti-apoptotic members such Bcl-2 and Bcl-XL, which protect mitochondrial 
integrity by counteracting the pro-apoptotic proteins, can also inhibit autophagy by 
sequestering the autophagic protein Beclin-1, that also contains BH3 domain. Hence, in 
many cases activation or increased expression of BH3-only proteins, such as Puma and 
Bad, can induce autophagy by competitive disruption of Bcl-2/ or Bcl-XL/Beclin-1 
interaction [90–93]. Moreover, Bcl-2/adenovirus E1B 9-Kda-interacting protein 3 
(BNIP3), an atypical pro-apoptotic BH3-only protein, may disturb mitochondrial 
function. BNIP3 dimerization on the outer mitochondrial membrane in response to 
cellular stress has been associated with cell death and heterodimers BNIP3/Bax can 
promote conformational modification of Bak resulting apoptosis by intrinsic pathway 
[90,94]. Moreover, BNIP3 in the cytosol and mitochondrial outer membrane [94] can 
induce mitochondrial autophagy by interaction with autophagy protein LC3 [90]. In our 
study it was well evidenced that ConBr can both, induce LC3I cleavage (30 and 50 
µg/mL), increment AVO formation, inhibit mTORC1 and increase expression and 
dimerization of BNIP3, which are events associated with autophagy. When we inhibited 
autophagy with 3-MA (2mM), it was observed that ConBr cytotoxicity against glioma 
cells decreased as evaluated by MTT assay (Fig. 6I). This finding suggests that ConBr 
may trigger autophagy in glioma cells as a mechanism of cell death [95,96]. 
Studies showed that ConA after binding to mannose moiety present in 
glycoproteins expressed on extracellular membranes was internalized and associated to 
the mitochondria surface, via clathrin-mediated endocytosis. This event was 
accompanied by a decrease of mitochondrial membrane pot ntial that initiates 
autophagy by inductions of BNIP3, Beclin-1 and LC3II [25,97]. We observed by 
transmission electron microscopy (Fig. 6C) the presence of double membrane vesicles, 
smaller than the autophagosomes, containing material indoor that were not observed in 










product of ConBr endocytosis. However, this possibility deserves to be investigated in 
future studies. 
One interesting point in our study was to show thatpre-treatment with FLICE-
inhibitor abrogated the ConBr-dependent cytotoxicity (Fig. 5I). This result suggests the 
possibility of a cell death receptor modulated by ConBr. Notable, the receptor TRAIL-
R1 (DR4) and –R2 (DR5) are glycoproteins which the signaling module leads to 
caspase-8/caspase-3 activation promoting cell death [98,99]. It is interesting that the 
lectin Moringa-G, the Gal-specific Black mulberry (Morus nigra) lectin, induced 
cleavage of caspases 8, 9, and 3 leading Jukat cells death, an effect that was hampered 
in cells that were deficient in caspase 8-10, caspase 9, or FADD [99]. In spite the 
potential modulation of TRAIL receptor by ConBr, docking assay did not show a 
substantial interaction of lectin with the glycans expressed on TRAIL-DR4 or –DR5 
(data not shown). 
Moreover, it has been also documented a crosstalk between autophagy and 
apoptosis, where caspase-mediated cleavage of Atg5 and Beclin-1 switches autophagy 
to apoptosis, while the cleavage of Atg4D results in a truncated product with increased 
autophagic activity, via activation of LC3 [47,101]. To investigate this mechanism, we 
performed pre-treatment of C6 cells with 3-MA and FLICE-inhibitor (Fig. 7). The 
results indicated that both inhibitors counteracted the cytotoxicity induced by ConBr, as 
evaluated by MTT assay, and in the same way, they also abrogated the ConBr-induced 
increasing of Puma, BNIP3 and LC3II immunocontent. It is documented that FLICE 
inhibitor can also directly bind Atg3 and impede autophagy by preventing Atg3 from 
binding and processing of microtubule-associated protein 1A/1B-light chain 3 (LC3) 
[102,103]. Taken together, the results suggest: i) ConBr promotes autophagy; ii) this 
process appears to mediate ConBr toxicity on C6 cells; iii) ConBr promote 
augmentation of some apoptotic features; iv) these events are partially dependent of 
autophagic pathway and caspase 8. 
Finally, our results suggest that ConBr displays cancer cell selectivity, since 
healthy astrocytes showed no change in response to l ctin treatment, while primary 
culture of GBM1, showed changes of cell morphology and decreased cell viability in 
response to ConBr treatment. Such selectivity might be attributed to expression of 
glycosylated targets for ConBr in cancer cells but not in health astrocytes (Fig. 8) [104]. 
Therefore, it is reasonable to hypothesize that selectivity of lectins to cancer cells results 












Our study shows the cytotoxic effect of ConBr against C6 glioma cells, which 
seems to involve mechanisms dependent on caspase-8 nd autophagy signaling to 
induce cell death. Cytostatic/antimigration effects also occurred at lower ConBr 
concentrations. Our working model (Fig. 9) also shows that ConBr, through interaction 
with glycans present in glioma cell surface targets, triggers p38MAPK and JNK (p46/54) 
activation and ERK1/2, Akt and mTORC1 inhibition. The decrease of Akt/mTORC1 
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Figure 1. ConBr decreases cell viability in C6 glioma cell. C6 glioma cells were 
treated for 3, 6, 12, 24 and 48 h with vehicle (HEPES-saline buffer; control) or 1, 10, 30 
and 50 µg/mL ConBr. Thereafter, cell morphology, cell viability and PI incorporation 
assays were performed. A) MTT cell viability assay after ConBr treatment. B) LDH 
assay after 12 and 24 h of ConBr treatment. C) Representative images of cell 
morphology alterations in response to ConBr treatmen . D) Representative images 
comparing effect of ConBr at 10 and 50 µg/mL compared to control for 6 and 24 h of 
treatment and E) quantification of PI staining in response to ConBr treatment for 3, 6, 
12, 24 and 48 h. The scale bar represents 50 μm. Four independent experiments were 
performed in triplicate. Data quantification express d as a percentage of control 
(considered 100%), and the values are presented as me n ± SEM. * p<0.05, ** p<0.01 
and *** p<0.001, as compared to control. One-way or Two-way ANOVA when 
appropriate followed by the Bonferroni post-hoc test
 
Figure 2. ConBr cytotoxicity relies on three-dimensional structure and 
carbohydrate-recognition domain. C6 glioma cells were treated for 24 h with vehicle 
or denatured/native/blocked ConBr. A) Representative microphotographs of cell 
morphology alterations in response to ConBr treatmen . The scale bar represents 100 
μm. B) MTT cell viability assay after ConBr treatment. Four independent experiments 
were performed in triplicate. Data quantification expressed as a percentage of control 
(considered 100%), and the values are presented as me n ± SEM. ** p<0.01 and *** 
p<0.001, as compared to control. ## p<0.01 as compared to treatment. Two-way 
ANOVA followed by the Bonferroni post-hoc test.  
 
Figure 3. ConBr decreases cell migration in C6 cell and might interact with MMP-
1 glycans. A) Effect of ConBr at 1, 10, 30 and 50 µg/mL on C6 glioma cell migration at 
different treatment endpoints. The scale bar represnts 200 μm. The graphs show the 
magnitude of cell migration inhibition by lectins. B) Representative image of cell 
migration/invasion in transwell assay as assessed by inverted microscopy. The scale bar 
represents 200 μm. The graphs show the magnitude of cell migration inhibition by 
lectins.  ** p<0.01 and *** p<0.001, as compared to c ntrol. ## p<0.01 and ### 










followed by the Bonferroni post-hoc test. C) MMP-1 glycan (T012) present in tumor 
cells. D) Interaction between ConBr (green) and MMP-1 (brown) via glycosylation 
(yellow; T012), in cartoon representation. 
 
Figure 4. ConBr increased JNKp46/p54 and p38MAPK  phosphorylation and 
decreased ERK1/2 and Akt phosphorylation. A) Representative Western blot of 
tested proteins and quantification of phospho- and total B) JNKp54, C) JNKp46, D) 
ERK1, E) ERK2, F) p38MAPK and G) Akt. The phosphorylation level of each protein 
was determined by the ratio of the O.D. of the phosrylated band over the O.D. of the 
total band. * p<0.05, ** p<0.01, *** p<0.001 as compared to control. One-way 
ANOVA followed by the Bonferroni post-hoc test.  
 
Figure 5. ConBr effects upon apoptosis and mitochondrial function markers.  A) 
Dot plot representation of flow cytometry of C6 cells treated with ConBr for 6 h 
(10,000 events per sample are shown). B) Caspase-3 activity assay in C6 cells treated 
for 6 h with varying concentrations of ConBr. C) ROS production after 6 h of treatment 
with vehicle or ConBr. D) Representative images comparing effect of ConBr at 50 
µg/mL compared to control and E) quantification of mitochondrial membrane potential 
as evaluated by JC-1 assay in C6 cells treated for 6 h. F) Representative Western blot of 
proteins and densitometry quantification of G) BNIP3 and H) Bak protein. I) Effect of 
FLICE/caspase-8-inhibitor (2 µM) on cell viability of C6 cells treated for 24 h with 
ConBr as assessed by MTT assay. Data are expressed a  a percentage of control 
(considered 100%), and the values are presented as me n ± SEM. For all analyses, four 
independent experiments were performed. * p<0.05, ** p<0.01 and *** p<0.001, as 
compared to control. # p< 0.05 and ### p<0.001 as compared to treatment. One-way or 
Two-way ANOVA when appropriate followed by the Bonferroni post-hoc test 
 
Figure 6. ConBr treatment induces autophagy-mediated death cell. A) 
Representative Acridine Orange (AO) staining images of 10 and 50 µg/mL ConBr 
treatments for 12 and 24 h and B) quantification of AO staining in response to ConBr at 
various time points (3, 6, 12, 24 and 48 h). Chromatin (CR) and acidic vesicle 
organelles (AVO) were detected in green and red channels, respectively. The scale bar 
represents 100 μm. C) TEM microscopy of C6 cells treated with 30 μg/mL ConBr or 










autophagosomes (Magnification of 6,000 x). D  Representative Western blot of proteins 
and quantification of E) phospho- and total-mTORC1, F) Beclin-1, G) Atg-7 and H) 
LC3 proteins in C6 cells treated for 12 h with ConBr. I) Effect of 3-MA (2 mM) and J) 
CQ (10 µM) on cell viability of C6 cells submitted to lectin treatment as evaluated by 
MTT assay. Data are expressed as a percentage of control (considered 100%), and the 
values are presented as mean ± SEM. For all analyses, four independent experiments 
were performed. * p<0.05, ** p<0.01 and *** p<0.001, as compared to control. # p< 
0.05 and ### p<0.001 as compared to treatment. One-way or Two-way ANOVA when 
appropriate followed by the Bonferroni post-hoc test. 
 
Figure 7. ConBr treatment yield crosstalk mechanism between activate caspase-8 
and autophagic degradation. C6 cells were treated for 6 h with 2 µM of FLICE 
inhibitor or 2 mM 3-MA for 1 h (as pretreatment of cells), and cells were co-incubated 
with 30 µg/mL ConBr for 12 or 24 h. A) Representative microphotographs of C6 cells 
morphology alterations in response to treatment (24 h). B) MTT cell viability assay 
performed 24 h after ConBr treatment in the presence/absence of 3-MA and FLICE 
inhibitor. C) Representative Western blot and densitometry quantification of D) BNIP3, 
E) Puma, F) Bad and G) LC3 proteins. Four independent experiments were performed. 
Quantification of data is expressed as a percentage of control (considered 100%), and 
the values are presented as mean ± SEM. ** p<0.01 and *** p<0.001, as compared to 
control. # p< 0.05, ## p<0.01 and ### p<0.001 as compared co-treatment 
(inhibitor/ConBr) to 30µg/mL ConBr. One-way or Two-way ANOVA when appropriate 
followed by the Bonferroni post-hoc test 
 
Figure 8. ConBr treatment does not alter viability of primary astrocytes. A) 
Representative optical microscopy images of astrocyes in culture after 24 h treatment 
with different ConBr concentrations. The scale bar represents 100 μm. B) MTT cell 
viability in response to ConBr treatment (24 h). C  Representative images of Hoechst/PI 
and D) Acridine Orange staining of astrocytes after 24 h ConBr exposure. The scale bar 
represents 100 μm. For all analyses, four independent experiments were performed. 
One-way ANOVA followed by the Bonferroni post-hoc tes .  
 
Figure 9. Schematic overview of ConBr effects on C6 glioma cells. ConBr binding 










decrease of cell viability with increasing p38MAPK and JNK (p46/54) phosphorylation. 
This effect is accompanied by decrease of ERK1/2 and Akt activity, as well as 
inhibition of cell migration and cell survival. Noteworthy, the inhibition of 
Akt/mTORC1 pathway by ConBr may be associated with activation of autophagic 
processes, with cleavage of LC3 leading to cell death and apparently inhibiting 
mitochondrial ROS production. This complex anti-glioma activity of ConBr, might 
involve crosstalk mechanisms involving caspase-8 and utophagic pathways leading 
glioma cell death. This figure was produced using Servier Medical Art 
























Table 1. Molecular docking scores between ConBr and glycans found in MMP-1. 































a nomenclature given to glycans referring to Supplementary Figures X1 and X2. 











































































ConBr lectin inhibits cell migration and promotes C6 glioma cell death by autophagy. 
ConBr-induced cell death and autophagy depends upon caspase-8 activity. 
ConBr stimulates p38MAPK and JNK and inhibits ERK, Akt and mTORC1 in glioma 
cells. 
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